Subscribe To
immix biopharma completes 3rd nxc-201 engineering batch at its u.s. car-t manufacturing site
Successful completion supports expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S. NXC-201 is manufactured at o...
October 16, 2023, 1:05 pm
immix (immx) up on orphan drug tag for al amyloidosis therapy
immix (IMMX) gets ODD designation in the United States for lead candidate NXC-201 for the treatment of ...
September 22, 2023, 1:31 pm
Nexcella, immix biopharma subsidiary, to present at the bank of america 2023 healthcare trailblazers private company conference
LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) — immix Biopharma, Inc. (Nasdaq: IMMX) (“...
September 7, 2023, 12:41 pm
immix biopharma announces dr. suzanne lentzsch, director of the multiple myeloma and amyloidosis program at the college of physicians and surgeons of columbia university and at new york presbyterian h
Dr. Lentzsch joins the Nexcella Scientific Advisory Board with decades of experience treating patients with AL Amyloidosis and multiple myeloma and se...
September 1, 2023, 12:39 pm
immix biopharma subsidiary nexcella announces commencement of nxc-201 engineering batches at its u.s. car-t manufacturing site
U.S. engineering batches support planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the United States Engineeri...
May 26, 2023, 1:53 pm
immix biopharma announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinic
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...
May 21, 2023, 8:00 pm
immix biopharma announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinic
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...
May 21, 2023, 8:00 pm
immix biopharma announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinic
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...
May 21, 2023, 8:00 pm
immix biopharma announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinic
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...
May 21, 2023, 8:00 pm
immix biopharma confirms no exposure to silicon valley bank or silvergate bank
LOS ANGELES, March 10, 2023 (GLOBE NEWSWIRE) — immix Biopharma, Inc. (Nasdaq: IMMX) (“...
March 11, 2023, 12:45 am
Nexcella, inc., a subsidiary of immix biopharma, announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...
December 28, 2022, 1:00 pm
Nexcella, inc., a subsidiary of immix biopharma, announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...
December 28, 2022, 1:00 pm
Nexcella, inc., a subsidiary of immix biopharma, announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...
December 28, 2022, 1:00 pm
Nexcella, inc., a subsidiary of immix biopharma, announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...
December 28, 2022, 1:00 pm
Nexcella, inc., a subsidiary of immix biopharma, announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...
December 28, 2022, 1:00 pm
Nexcella, inc., a subsidiary of immix biopharma, announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...
December 28, 2022, 1:00 pm
Nexcella, inc., a subsidiary of immix biopharma, announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...
December 28, 2022, 1:00 pm
Nexcella, inc., a subsidiary of immix biopharma, announces poster presentation at the european society for blood and marrow transplantation and european hematology association 5th annual european car
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands Februa...
December 28, 2022, 1:00 pm